Contact Us
Posted: March 28, 2019
  • Company News

Abingdon Health appoint Leigh Thomas as Business Development Director

28 March 2019; York, UK: Abingdon Health is pleased to announce the appointment of Leigh Thomas to the newly created role of Business Development Director. In this role, Leigh will be responsible for identifying and leading strategic business development opportunities, alliances and product development opportunities for Abingdon. Leigh will report into CEO Chris Yates.

Leigh previously spent 16 years in various senior sales roles within BBI Solutions including periods as Chief Commercial Officer and Sales Director of BBI Solutions’ OEM contract services division.

Chris Yates, CEO of Abingdon Health, commented:  “I’m delighted to welcome Leigh to the Abingdon group during an exciting time in our development.  We are seeing strong growth as a result of our continued focus on building long-term business relationships, excellent customer service and our commitment to product quality. Leigh brings a wealth of commercial experience within the point of care diagnostics market which will help support our ambitious growth plans.”

Leigh Thomas, “Abingdon Health has a strong pedigree in lateral flow diagnostics, I am delighted to be joining the team as the company puts its growth plan into action. There is a growing need for fast, accurate and reliable lateral flow assays integrated with user-friendly reader and data handling solutions, across a variety of sectors. Abingdon Health is well placed to support this demand and I look forward to making a contribution to the growing success and expansion of the company.”

About Abingdon Health

Abingdon is a UK-based developer and manufacturer of lateral flow immunoassay tests and readers.

Abingdon offers development and manufacturing services for customers looking to develop new assays or looking to transfer existing laboratory-based assays to a lateral flow format. Abingdon takes projects from initial concept through to routine and large-scale manufacturing. Abingdon’s patented lateral flow reader, the ADxLR5®, is CE marked and FDA registered and can be fully customised to meet the needs of clients looking for a quantitative solution for a lateral flow assay. Internally Abingdon is focused on developing lateral flow assays in partnership with key opinion leaders that meet significant unmet needs.

In January 2019 Abingdon closed a growth capital funding round NPIF – Mercia Equity Finance, which is managed by Mercia Fund Managers and part of the Northern Powerhouse Investment Fund.

Abingdon is headquartered in York, England.